Interestingly, sunitinib also reduced ERK1/2 and BIM phosphorylation (Supplementary Figure 4A), suggesting that this inhibitor also affects MAPK pathway, as previously described for other cancer types (Chahal et al., 2010; Fenton et al., 2010). This evidence concerns the gene MAPK3 and cancer.